Routine Mammography Screening Increases Except Among Minorities and the Elderly

OncologyONCOLOGY Vol 16 No 1
Volume 16
Issue 1

The number of women receiving mammograms is higher than ever, according to the results of a study conducted by the Board of Sponsors for National Breast Cancer Awareness Month (NBCAM). The study found that more women are getting

The number of women receiving mammograms is higher thanever, according to the results of a study conducted by the Board of Sponsors forNational Breast Cancer Awareness Month (NBCAM). The study found that more womenare getting annual mammograms and that cancer mortality rates are declining.

Despite this encouraging news, the study also found that minority and elderlywomen are far less likely to have regular screenings (every 1 or 2 years). Thistrend is reflected in the breast cancer mortality rates among black women, asthey are more likely to be diagnosed with breast cancer at a later, lesstreatable stage.

"We’ve come a long way from the time that breast cancer screening wasnot a test that women routinely had done, but we know that more needs to be doneto reach minority women," said National Breast Cancer Awareness MonthNational Coordinator Susan Nathanson. "While the efforts of NBCAM and ourmembers have contributed to the increase in mammography rates and subsequentdecrease in death rates, we all need to focus on helping minority andlower-income women understand the benefits of mammography screening and theresources that are available to them to practice good breast health."

Factors Affecting Screening

The study found that regular screening of minority women may be hindered bylow income, no insurance coverage, or lack of information. Overall, theproportion of women aged 40 years and older receiving mammograms rose steadily,from 58.3% in 1990 to 76.1% in 2000. "For the past 10 to 15 years, we havemade mammography available throughout this country to more and more women,"said Ellen Mendelson, MD, director of breast imaging at Northwestern MemorialHospital and professor of radiology at Northwestern University Medical School."However, we’re concerned that minority groups haven’t taken advantageof the opportunities that mammography can provide."

Moreover, the failure of physicians to discuss mammography with theirpatients may also be discouraging minority and elderly women from havingmammograms. Recommendation for mammography was found to be more frequent amongwomen who had a regular physician and health insurance. The study found thatsocioeconomic status, age, and other characteristics, excluding race andethnicity, were related to a physician recommendation for screening mammography.About 62% reported an adequate level of referrals for screening mammograms.

In addition, the shortage of diagnostic radiologists available to performmammograms, low reimbursement rates, and decline in the number of imagingcenters around the United States contribute to current and future access issues.Whether the closing of imaging centers and increased regulation to ensurequality services has significantly limited patient access to mammography remainsundetermined. The demand for routine or annual mammography will increase as thepopulation ages, and these issues must be monitored carefully to ensure thataccess to mammography is not put at risk.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content